hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06362356 id: 24-106 briefTitle: Microbial Metabolites and Outcomes of Pregnancy Study acronym: MMOPS overallStatus: RECRUITING date: 2024-03-05 date: 2026-12-31 date: 2026-12-31 date: 2024-04-12 date: 2024-04-18 name: The Cleveland Clinic class: OTHER briefSummary: Emerging data connect diet, the gut microbiota and its metabolites in cardiometabolic disease. Hypertensive disorders of pregnancy (HDP) are common and are a leading cause of maternal and neonatal morbidity. HDP likely share similar pathophysiology as cardiometabolic disease in non-pregnant people with a yet unrevealed role of diet and the gut microbiota, including systemic inflammation and endothelial dysfunction.
Despite high biological plausibility that nutrition, the gut microbiota and its metabolites may play a role in health and disease in pregnancy, there is a paucity of data regarding these associations, thus limiting advancement of the field. Similar to the proposed pathogenesis for diet, gut microbiota and the microbial metabolite trimethylamine-N-oxide (TMAO) in cardiovascular disease, we hypothesize that the interplay between maternal diet, the gut microbiota and its associated microbial metabolites play a mechanistic role in HDP. We propose to test this hypothesis in a racially-diverse US cohort to determine association with adverse pregnancy outcomes, specifically future development of HDP. We propose to prospectively collect plasma and urine TMAO throughout pregnancy from a cohort of 200 pregnant participants.
Through 1) characterizing plasma and urine TMAO levels across each trimester of pregnancy, and 2) assessment of this microbial metabolite as a predictor of development of HDP, we have the potential to identify a biomarker that would allow us to identify people at risk of HDP early in pregnancy and provide new opportunities for therapeutic interventions to improve maternal and neonatal outcomes. conditions: Hypertensive Disorder of Pregnancy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: TMAO level measure: TMAO level measure: TMAO level sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Cleveland Clinic status: RECRUITING city: Cleveland state: Ohio zip: 44195 country: United States name: Cara Dolin, M.D. role: CONTACT phone: 440-312-2229 email: dolinc@ccf.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06362343 id: PUMCH-Rivaroxaban-Monitoring briefTitle: The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics overallStatus: RECRUITING date: 2024-01-01 date: 2026-10-30 date: 2027-01-30 date: 2024-04-12 date: 2024-04-12 name: Peking Union Medical College Hospital class: OTHER name: Ruijin Hospital name: Xiangya Hospital of Central South University name: China-Japan Friendship Hospital briefSummary: 1. Integrate pharmacokinetic-pharmacodynamic (PK-PD) modeling and pharmacogenomics techniques to develop a population PK-PD model, aiming to explore monitoring and dose guidance schemes for Direct Oral Anticoagulants (DOACs).
3. Explore the correlation between drug concentrations, coagulation indices, and clinical outcomes of DOACs, defining the indications for DOACs testing and the overall monitoring process. conditions: Pulmonary Embolism studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: Rivaroxaban measure: Bleeding events measure: Recurrent thromboembolic events sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking Union Medical College Hospital status: RECRUITING city: Beijing state: Beijing zip: 100730 country: China name: Juhong Shi, M.D role: CONTACT phone: +8613701178492 email: shijh@pumch.cn name: Min Peng, M.D role: CONTACT phone: +8613581888792 email: pengmin@pumch.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06362330 id: 2022-SR-471 briefTitle: Multi-parametric MRI in Patients of Bladder Cancer overallStatus: RECRUITING date: 2021-07-01 date: 2024-05-30 date: 2024-06-30 date: 2024-04-12 date: 2024-04-12 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: Accurate preoperative detection of muscle-invasive bladder cancer remains a clinical challenge. The investigators aimed to develop and validate a knowledge-guided causal diagnostic network for the detection of muscle-invasive bladder cancer with multiparametric magnetic resonance imaging(MRI). conditions: Muscle-invasive Bladder Cancer conditions: Artificial Intelligence studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED name: magnetic resonance imaging measure: Muscle-invasive bladder cancer measure: Non-muscle-invasive bladder cancer sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Yu-Dong Zhang status: RECRUITING city: Nanjing zip: 210029 country: China name: Yu-Dong Zhang, MD;PHD role: CONTACT phone: 15805151704 email: njmu_zyd@163.com lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06362317 id: K5247 briefTitle: Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer overallStatus: RECRUITING date: 2024-03-06 date: 2025-03-06 date: 2026-03-06 date: 2024-04-12 date: 2024-04-12 name: Peking Union Medical College Hospital class: OTHER briefSummary: Explore the impact of the first-line application of Toripalimab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers conditions: Biliary Tract Neoplasms Immunotherapy studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 300 type: ESTIMATED name: Toripalimab name: Lenvatinib name: Gemox Chemotherapy（Gemox or GC） measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Progression-free survival (PFS) measure: Overall survival measure: Duration of response measure: Clinical benefit rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH) status: RECRUITING city: Beijing state: Beijing zip: 100005 country: China name: Haitao Zhao, Professor role: CONTACT phone: +861069156042 email: zhaoht@pumch.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06362304 id: 2024-DG-01 briefTitle: 99mTc-CNDG SPECT/CT in Brain Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02 date: 2025-04 date: 2024-04-12 date: 2024-04-12 name: Peking Union Medical College Hospital class: OTHER briefSummary: The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:
Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard. conditions: Intracranial Tumor studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ESTIMATED name: 99mTc-CNDG SPECT/CT measure: SUVmax sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06362291 id: 2023IR27 briefTitle: Comparison of MRI AI-cTB Versus Routine cTB in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial overallStatus: RECRUITING date: 2023-08-01 date: 2024-07-31 date: 2025-04-30 date: 2024-04-12 date: 2024-04-12 name: Peking University First Hospital class: OTHER briefSummary: The goal of this clinical trial is to compare the cancer detection rates of MRI artificial intelligence-guided cTB (AI-cTB) and routine cTB, and explore the added value of using AI for the guidance of cTB. The main questions it aims to answer are:
Receive AI-cTB or routine cTB. conditions: Prostate Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 340 type: ESTIMATED name: MRI-AI guided cognitive prostate targeted biopsy name: Routine cognitive prostate targeted biopsy measure: The clinically significant prostate cancer (csPCa) detection rate for targeted biopsy (TB) and TB combined with systematic biopsy (SB) measure: The PCa detection rate measure: The Gleason score (GS) of the biopsy sample measure: The GS of radical prostatectomy (RP) specimens sex: MALE minimumAge: 45 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University First Hospital status: RECRUITING city: Beijing state: Beijing zip: 100034 country: China name: Baowei Zhang role: CONTACT phone: +86 83572466 email: bdyyll@126.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06362278 id: 026 briefTitle: A Multi-omics Study of "Healthy" Premature CAD Patients overallStatus: RECRUITING date: 2024-03-20 date: 2025-12 date: 2025-12 date: 2024-04-12 date: 2024-04-12 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: The goal of this multi-center observational clinical trial is to investigate the genetic risk factors of patients with premature CAD and none traditional CAD risk factors through a multi-omics approach.
* How to optimize current primary prevention strategy for this rare CAD subgroup？ conditions: Coronary Artery Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 160 type: ESTIMATED name: multi-omics studies measure: common & rare variants associated with "healthy" pre-mature CAD phenotype measure: Unique metabolomic fingerprints associated with "healthy" pre-mature CAD phenotype sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu zip: 210000 country: China name: Chunjian Li, Phd、MD role: CONTACT phone: +86 13701465229 email: lijay@njmu.edu.cn lat: 32.06167 lon: 118.77778 facility: Qilu Hospital of Shangdong University status: ACTIVE_NOT_RECRUITING city: Jinan state: Shandong zip: 250012 country: China lat: 36.66833 lon: 116.99722 facility: The Second Affiliated Hospital of Zhejiang University Medical College status: ACTIVE_NOT_RECRUITING city: Hangzhou state: Zhejiang zip: 310009 country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06362265 id: 18437 id: I8H-MC-BDDB type: OTHER domain: Eli Lilly and Company briefTitle: A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-11 date: 2026-11 date: 2024-04-12 date: 2024-04-19 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days. conditions: Type 2 Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 22 type: ESTIMATED name: LY3209590 measure: Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3209590 measure: PK: Maximum Observed Plasma Concentration (Cmax) of LY3209590 measure: Change from Baseline in Fasting Glucose sex: ALL minimumAge: 10 Years maximumAge: 17 Years stdAges: CHILD facility: Honor Health Research Institute city: Scottsdale state: Arizona zip: 85258 country: United States lat: 33.50921 lon: -111.89903 facility: Children's Hospital Los Angeles city: Los Angeles state: California zip: 90027 country: United States lat: 34.05223 lon: -118.24368 facility: Children's Healthcare of Atlanta - Center for Advanced Pediatrics city: Atlanta state: Georgia zip: 30329 country: United States lat: 33.749 lon: -84.38798 facility: University of Louisville, Norton Children's Research Institute city: Louisville state: Kentucky zip: 40202 country: United States lat: 38.25424 lon: -85.75941 facility: Johns Hopkins University School of Medicine city: Baltimore state: Maryland zip: 21287 country: United States lat: 39.29038 lon: -76.61219 facility: Joslin Diabetes Center city: Boston state: Massachusetts zip: 02215 country: United States lat: 42.35843 lon: -71.05977 facility: UBMD Pediatrics city: Buffalo state: New York zip: 14203 country: United States lat: 42.88645 lon: -78.87837 facility: NYU Langone city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 facility: Cincinnati Children's Hospital Medical Center city: Cincinnati state: Ohio zip: 45229 country: United States lat: 39.12713 lon: -84.51435 facility: Children's Hospital of Philadelphia city: Philadelphia state: Pennsylvania zip: 19104 country: United States lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06362239 id: STUDY00003853 briefTitle: Prospective Home-Based Palliative Care and Hospice Study overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-10 date: 2027-10 date: 2024-04-12 date: 2024-04-12 name: Steven Smith class: OTHER name: Akron Children's Hospital name: Medical University of South Carolina name: Nemours Children's Hospital name: Baylor College of Medicine briefSummary: The purpose of this study is to test the hypothesis that the addition of home-based hospice and palliative care (HBHPC) will provide a reduction in health care utilization, improve quality of life, and facilitate goal-concordant care that is superior to inpatient and clinic pediatric palliative care (PPC) alone. conditions: Pediatric Palliative Care studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 250 type: ESTIMATED name: Study Surveys measure: Hospital Utilization Differences measure: Demographic Differences measure: Location of death differences sex: ALL maximumAge: 19 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06362226 id: HM20029491 briefTitle: OPTIMIZING OCULAR OUTCOMES: A DUAL-ARMED STUDY FOR PERIORBITAL BURN MANAGEMENT overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-08 date: 2026-10 date: 2024-04-12 date: 2024-04-12 name: Virginia Commonwealth University class: OTHER briefSummary: The purpose of this study is to evaluate the effectiveness in using subcutaneous 5-FU/Kenalog \& antibiotic ointment with vitamin E as different therapeutic adjuncts in the prevention of pathologic remodeling after periorbital burns. conditions: Periorbital Burns studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Steroid/Antibiotic name: 5-FU/Kenalog measure: Comparison of wound healing time measure: Comparison of infection rate measure: Comparison of complication rates measure: Comparison of pain level measure: Comparison of quality of life measure: Comparison of cosmetic outcome through the Vancouver scar scale (VSS) measure: Comparison of cosmetic outcome through the Patient Observer Scar Assessment Scale (POSAS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06362213 id: NL76924.029.22 briefTitle: Gaining Insight Into Dual Sensory Loss acronym: DSL overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-04 date: 2025-04 date: 2024-04-12 date: 2024-04-12 name: Amsterdam UMC, location VUmc class: OTHER name: Royal Dutch Visio briefSummary: The goal of this observational study is to explore difficulties in information access, mobility, communication and fatigue in people with combined vision and hearing impairments. The main question it aims to answer is:
Participants will fill out questionnaires and the researchers will measure their vision and hearing functions. conditions: Dual Sensory Impairment of Vision and Hearing studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 300 type: ESTIMATED measure: information access measure: mobility measure: communication measure: fatigue sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Amsterdam UMC, location VUmc city: Amsterdam state: Noord Holland zip: 1081 HV country: Netherlands lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06362200 id: LYG20230083 briefTitle: The Validation and Biological Index Studies on the Improved Social Function of ASD by 40 Hz tACS overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2028-12-31 date: 2028-12-31 date: 2024-04-12 date: 2024-04-12 name: Central South University class: OTHER briefSummary: In this proposed study, tACS will be used to intervene in the autism spectrum disorders of children and adolescents, and the efficacy of this intervention method will be evaluated, as well as the internal mechanism of adolescents' autism spectrum disorders will be discussed. conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: 40 Hz tACS intervention measure: Autism assessment assessment index measure: EEG physiological detection index measure: Magnetic resonance detection index measure: Eye movement index measure: Emotion recognition index measure: Understanding of social interaction index measure: Understanding of thoughts and intentions index measure: Social Communication Changes index measure: Stereotyped behavior index measure: Sensory index measure: Abnormal behavior indicator measure: Sleep index measure: Plasma Metabolite Levels Assessment measure: Safety evaluation SAFTEE indicator sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06362187 id: STUDY00003238 briefTitle: VR Pilot for Pancreatitis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2026-05 date: 2024-04-12 date: 2024-04-12 name: Cedars-Sinai Medical Center class: OTHER briefSummary: The purpose of the research is to test the feasibility and preliminary impact of a home-based, standardized, gut-directed, virtual reality cognitive behavioral therapy (VR CBT) on clinical and functional outcomes of patients with chronic pancreatitis (CP) and recurrent acute pancreatitis (RAP) pain. The primary research procedures are questionnaires and biometric Fitbit data. The study will enroll adult patients with CP or RAP. conditions: Chronic Pancreatitis conditions: Recurrent Pancreatitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, double-blind, controlled primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Gut Directed VR name: Sham Control VR measure: Feasibility of home-based VR measure: Impact of home-based VR sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marissa Podell city: Los Angeles state: California zip: 90048 country: United States lat: 34.05223 lon: -118.24368 hasResults: False
nctId: NCT06362174 id: SHEBA-22-9902-SBH-CTIL briefTitle: Capsule & Omics for pRedicting Exacerbation of Crohn's Disease acronym: CORE-CD overallStatus: ACTIVE_NOT_RECRUITING date: 2023-02-07 date: 2025-12-31 date: 2025-12-31 date: 2024-04-12 date: 2024-04-12 name: Sheba Medical Center class: OTHER_GOV briefSummary: The research group have previously evaluated the benefit of serial consecutive capsule endoscopy as monitoring tool for Crohn's disease in remission, demonstrating its superior accuracy for disclosing inflammation and for prediction of flares in comparison to other diagnostic modalities such as magnetic resonance enterography and inflammatory biomarkers. Subsequently, deep learning algorithms had developed to provide excellent accuracy for identification and grading of ulcers and intestinal strictures on capsule endoscopy still images. The investigators will advance this knowledge using a parallel two-parts approach. conditions: Crohn's Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 62 type: ACTUAL measure: Crohn's Disease Activity Index score (CDAI) measure: Disease related complications measure: disease related hospitalization measure: Change of crohn's disease medications measure: opinion of the principle investigator (PI) or the treating physician measure: The rate of clinical flare accompanied by objective signs of mucosal inflammation. measure: The rate of inflammatory worsening with/without accompanying clinical symptoms sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Sheba Medical Center city: Tel-Hashomer country: Israel lat: 32.04195 lon: 34.85623 hasResults: False
nctId: NCT06362161 id: IRB-300011066 briefTitle: Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-05-01 date: 2028-12-31 date: 2024-04-12 date: 2024-04-12 name: University of Alabama at Birmingham class: OTHER briefSummary: The purpose of this study is to help providers develop an interdisciplinary treatment pathway for functional neurological disorder (FND) at University of Alabama at Birmingham (UAB), and will involve psychiatry, speech therapy, physical therapy, and occupational therapy. The study will also help providers to evaluate the treatment pathway and publish results regarding the process and outcomes. conditions: Functional Neurological Disorder conditions: Convulsion, Non-Epileptic conditions: Functional Seizure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 1100 type: ESTIMATED measure: Patient Demographic Information measure: Hospital Anxiety and Depression Scale (HADS) measure: ASM 121 functional assessment definitions measure: SF-36 (subjective health and wellbeing) measure: Work and Social Adjustment Scale (WSAS) measure: Patient Health Questionnaire 15 measure: Dizziness Handicap Inventory measure: Dizziness Symptom Profile measure: Adult Tic Questionnaire (ATQ) measure: Child Self-Report Tic Questionnaire measure: Parent Tic Questionnaire (PTQ) measure: Seizure Questionnaire measure: Level 2-Somatic Symptom report measure: Revised Children's Anxiety and Depression Scale (RCADS) measure: Functional Disability Inventory (FDI) measure: Impact on the Family Scale measure: Pediatric Quality of Life (Peds-QL) measure: Healthcare Utility Questionnaire measure: Assessment of control over symptoms sex: ALL minimumAge: 8 Years maximumAge: 89 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama at Birmingham city: Birmingham state: Alabama zip: 35294 country: United States name: Michelle Bumpers role: CONTACT lat: 33.52066 lon: -86.80249 hasResults: False